Charles Roach, MD
Neurology · Saint Louis, MONPI 1588158570
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,141 of the $1,711 with a category attached, or 66.7%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 86.0% of it on its own, with 3 other manufacturers making up the rest.
Across 13 payments — averaging $131.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- AstraZeneca$110
- Amicus Therapeutics, Inc.$84
- Argenx US, Inc.$46
Across 10 payments — averaging $8614.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$84K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Travel & lodging$1,14167%
- Food & beverage$57033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $1,472 |
| AstraZeneca | 1 | $110 |
| Amicus Therapeutics, Inc. | 1 | $84 |
| Argenx US, Inc. | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WAINUA$110
How this compares
$1,711 in reported general payments places this provider in the 55th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 41 | $580,399 |
| Riluzole | 52 | $3,363 |
| Mycophenolate Mofetil | 16 | $2,406 |
| Pyridostigmine Bromide | 23 | $1,455 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 23 | $1,096 |
| Gabapentin | 60 | $1,034 |
| Glycopyrrolate | 16 | $1,010 |
| Pregabalin | 36 | $1,004 |
| Prednisone | 85 | $817 |
| Oxcarbazepine | 32 | $559 |
| Atropine Sulfate | 29 | $527 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 16 | $514 |
| Duloxetine Hcl | 57 | $501 |
| MethotrexateMethotrexate Sodium | 33 | $404 |
| Baclofen | 14 | $176 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Louis
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Robert NaismithSaint Louis$677K
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- David HoltzmanSaint Louis$165K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.